Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + cytarabine + fludarabine
- Development stage
- Phase 2
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of bortezomib (a proteasome inhibitor), cytarabine (a nucleoside analog), and fludarabine (a purine nucleoside analog). This regimen is primarily used for treating relapsed/refractory leukemia, particularly acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The combination leverages synergistic effects between these drugs to enhance anti-cancer activity. Bortezomib may potentiate fludarabine activity by inhibiting DNA repair, while fludarabine increases the efficacy of cytarabine by enhancing the production of its active metabolite.
- Other names
- FLAG with Bortezomib
02
Targets
Beyond the preview
Go deeper on bortezomib + cytarabine + fludarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + cytarabine + fludarabine.